Trials / Completed
CompletedNCT01174355
A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)
A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- NeuroDerm Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ND0801 | Confidential |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2010-08-03
- Last updated
- 2019-12-05
Locations
2 sites across 1 country: Israel
Source: ClinicalTrials.gov record NCT01174355. Inclusion in this directory is not an endorsement.